Strategies for Group A Streptococcal Prevention
A 组链球菌预防策略
基本信息
- 批准号:7394401
- 负责人:
- 金额:$ 12.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-05-05 至 2009-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by the applicant): Pharyngitis accounts for 6.4% of office visits and 10% of total antibiotic prescriptions in the U.S. Although viruses are the most common cause of pharyngitis, approximately 15-36% of children will have a bacterial cause such as Group A Streptococcus (GAS). Ideally, physicians would treat only bacterial causes with antibiotics. However, studies have found that 70-80% of children who are seen for pharyngitis will receive an antibiotic prescription, suggesting that physicians may be excessively recommending antibiotic use. Such overuse of antibiotics has led to growing concerns over the development of antibiotic resistance in the community. GAS vaccine trials are underway in the U.S. and Canada. If the vaccine proves efficacious, it will not only have the potential to prevent GAS disease such as pharyngitis, invasive disease, and rheumatic fever, but it may also reduce unnecessary antibiotic prescribing and rates of resistance in the community. Decisions will need to be made about reasonable and cost-effective vaccine use once it becomes available. The goal of this proposal is to enhance our understanding of how to incorporate patient preferences and advanced modeling methods in evaluating the cost-effectiveness of interventions against infections. The candidate will address 4 specific aims: (1) To determine the societal costs and health state preferences for GAS infection such as pharyngitis; (2) To create a decision-analytic model to estimate the costs and health outcomes of selective vaccination strategies to prevent invasive GAS disease; (3) To determine the cost-effectiveness of universal vaccination strategies for infants and/or children through mathematical modeling; and (4) To evaluate the costs and outcomes of current management strategies for pharyngitis and model the potential downstream impact of a GAS vaccine. The overall goal of this K08 Award is to contribute to the professional, academic, and research development of the candidate. Her commitment to improving the health outcomes of children combined with her expertise in pediatric infectious diseases provides a strong foundation for this proposal. In addition to pursuing formal training at Harvard School of Public Health and the Kennedy School of Government, she will receive guidance and support from a team of accomplished mentors and advisors. During her K Award, she hopes to establish herself as a multidisciplinary researcher in the fields of decision sciences, infectious disease modeling, and health policy.
描述(由申请人提供):在美国,咽炎占办公室就诊的6.4%,抗生素处方总数的10%。虽然病毒是导致咽炎的最常见原因,但大约15%-36%的儿童会有细菌性原因,如A组链球菌(GAS)。理想情况下,医生只会用抗生素治疗细菌引起的疾病。然而,研究发现,被诊断为咽炎的儿童中有70%-80%会收到抗生素处方,这表明医生可能过度推荐使用抗生素。这种过度使用抗生素的做法导致人们越来越关注社区对抗生素耐药性的发展。气体疫苗试验正在美国和加拿大进行。如果疫苗被证明有效,它不仅有可能预防咽炎、侵袭性疾病和风湿热等气体疾病,而且还可能减少社区不必要的抗生素处方和耐药率。一旦疫苗可用,就需要就合理和具有成本效益的疫苗使用做出决定。这项建议的目标是加强我们对如何将患者的偏好和先进的建模方法纳入评估预防感染干预措施的成本效益的理解。候选人将致力于4个具体目标:(1)确定咽炎等气体感染的社会成本和健康状况偏好;(2)创建决策分析模型,以估计预防侵袭性气体疾病的选择性疫苗接种策略的成本和健康结果;(3)通过数学建模确定针对婴儿和/或儿童的通用疫苗接种策略的成本效益;(4)评估目前咽炎管理策略的成本和结果,并对气体疫苗潜在的下游影响进行建模。这个K08奖项的总体目标是为候选人的专业、学术和研究发展做出贡献。她致力于改善儿童的健康状况,再加上她在儿科传染病方面的专长,为这一提议奠定了坚实的基础。除了在哈佛大学公共卫生学院和肯尼迪政府学院接受正式培训外,她还将得到一个由经验丰富的导师和顾问组成的团队的指导和支持。在她的K奖期间,她希望在决策科学、传染病建模和卫生政策领域确立自己的多学科研究员地位。
项目成果
期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Gaps in vaccine financing for underinsured children in the United States.
美国保险不足儿童的疫苗融资存在缺口。
- DOI:10.1001/jama.298.6.638
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Lee,GraceM;Santoli,JeanneM;Hannan,Claire;Messonnier,MarkL;Sabin,JamesE;Rusinak,Donna;Gay,Charlene;Lett,SusanM;Lieu,TracyA
- 通讯作者:Lieu,TracyA
Preferences for health outcomes associated with Group A Streptococcal disease and vaccination.
- DOI:10.1186/1477-7525-8-28
- 发表时间:2010-03-12
- 期刊:
- 影响因子:3.6
- 作者:Lee GM;Salomon JA;Gay C;Hammitt JK
- 通讯作者:Hammitt JK
Varicella vaccination in adults: is it cost-effective?
成人水痘疫苗接种:是否具有成本效益?
- DOI:10.1086/512744
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Lee,GraceM
- 通讯作者:Lee,GraceM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Grace M Lee其他文献
Cultural Industries
文化产业
- DOI:
- 发表时间:
2020 - 期刊:
- 影响因子:0
- 作者:
Andrew G Wu;Gowri Madhavan;Kathy Deakins;Dana Evans;Angela Hayward;Caitlin Pugh;Angela Carter Stutts;Laurie Mustin;Katherine C. Staubach;Patricia Sisson;Maitreya Coffey;Anne Lyren;Grace M Lee;Sameer Gupta;Lucy Pereira;Gregory P. Priebe - 通讯作者:
Gregory P. Priebe
Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005: Demand, supply and seasonality
2005 年美国大型管理式医疗机构中青少年对脑膜炎球菌结合疫苗的使用情况:需求、供应和季节性
- DOI:
- 发表时间:
2009 - 期刊:
- 影响因子:3.7
- 作者:
S. Lorick;Daniel Fishbein;Eric Weintraub;Pascale M Wortley;Grace M Lee;Fangjun Zhou;Robert Davis - 通讯作者:
Robert Davis
Complement Activation As a Biomarker for Platelet Activating Antibodies in Heparin-Induced Thrombocytopenia (HIT)
- DOI:
10.1182/blood-2024-208062 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Sooho S Myoung;Samuel Francis;Jonah Chen;Grace M Lee;Lubica Rauova;Mortimer Poncz;Douglas B. Cines;Maragatha Kuchibhatla;Sanjay Khandelwal;Gow Arepally - 通讯作者:
Gow Arepally
Red Cell Exchange Decreases Sickle RBC-Induced Release of MPO from Neutrophils
- DOI:
10.1182/blood-2024-207819 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Y-Nhi Bui;Kimberly Boyle;Milena Batchvarova;Martha Delahunty;Marilyn J. Telen;Grace M Lee - 通讯作者:
Grace M Lee
Grace M Lee的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Grace M Lee', 18)}}的其他基金
Defining and Preventing Ventilator-Associated Complications in Pediatrics
儿科呼吸机相关并发症的定义和预防
- 批准号:
8642155 - 财政年份:2013
- 资助金额:
$ 12.9万 - 项目类别:
Defining and Preventing Ventilator-Associated Complications in Pediatrics
儿科呼吸机相关并发症的定义和预防
- 批准号:
8414054 - 财政年份:2013
- 资助金额:
$ 12.9万 - 项目类别:
Defining and Preventing Ventilator-Associated Complications in Pediatrics
儿科呼吸机相关并发症的定义和预防
- 批准号:
8796722 - 财政年份:2013
- 资助金额:
$ 12.9万 - 项目类别:
Nonpayment for Preventable Complications: Impact on Hospital Practices and Health
可预防并发症不付款:对医院实践和健康的影响
- 批准号:
7701367 - 财政年份:2009
- 资助金额:
$ 12.9万 - 项目类别:
Preventing Avoidable Infectious Complications by Adjusting Payment (PAICAP)II
通过调整付款方式预防可避免的感染性并发症 (PAICAP)II
- 批准号:
8813055 - 财政年份:2009
- 资助金额:
$ 12.9万 - 项目类别:
Intended and Unintended Consequences of Nonpayment for Preventable Complications
不支付可预防并发症的有意和无意的后果
- 批准号:
8508789 - 财政年份:2009
- 资助金额:
$ 12.9万 - 项目类别:
Nonpayment for Preventable Complications: Impact on Hospital Practices and Health
可预防并发症不付款:对医院实践和健康的影响
- 批准号:
7897759 - 财政年份:2009
- 资助金额:
$ 12.9万 - 项目类别:
Intended and Unintended Consequences of Nonpayment for Preventable Complications
不支付可预防并发症的有意和无意的后果
- 批准号:
7785306 - 财政年份:2009
- 资助金额:
$ 12.9万 - 项目类别:
Intended and Unintended Consequences of Nonpayment for Preventable Complications
不支付可预防并发症的有意和无意的后果
- 批准号:
8111673 - 财政年份:2009
- 资助金额:
$ 12.9万 - 项目类别:
Intended and Unintended Consequences of Nonpayment for Preventable Complications
不支付可预防并发症的有意和无意的后果
- 批准号:
8299934 - 财政年份:2009
- 资助金额:
$ 12.9万 - 项目类别:
相似国自然基金
分泌蛋白IGFBP2在儿童Group3/Group4型髓母细胞瘤恶性进展中的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
大兴安岭火山湖Group I长链烯酮冷季节温标研究与过去2000年温度定量重建
- 批准号:42073070
- 批准年份:2020
- 资助金额:61 万元
- 项目类别:面上项目
近海沉积物中Marine Group I古菌新类群的发现、培养及其驱动碳氮循环的机制
- 批准号:92051115
- 批准年份:2020
- 资助金额:81.0 万元
- 项目类别:重大研究计划
MicroRNA靶向的漆酶基因及其所在Group 1 亚家族成员 调控水稻产量性状的功能机制
- 批准号:
- 批准年份:2019
- 资助金额:257 万元
- 项目类别:
超级增强子驱动的核心转录调控环路在Group_3亚型髓母细胞瘤的发病和治疗中的作用和机制
- 批准号:81972646
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
东北地区火山湖GroupⅠ类型的长链烯酮研究及其不饱和度温标的应用
- 批准号:41702187
- 批准年份:2017
- 资助金额:26.0 万元
- 项目类别:青年科学基金项目
中国源毕氏肠微孢子虫group 2基因型人兽共患特征的研究
- 批准号:31502055
- 批准年份:2015
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
人源Group IIE分泌型磷脂酶A2蛋白的结构生物学研究
- 批准号:31300670
- 批准年份:2013
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
连锁群选育法(Linkage Group Selection)在柔嫩艾美耳球虫表型相关基因研究中应用
- 批准号:30700601
- 批准年份:2007
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
虎尾草族核心群Chloris group的系统演化研究
- 批准号:30700043
- 批准年份:2007
- 资助金额:16.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Mechanisms of Group B Streptococcal Pathogenesis in the Diabetic Wound
糖尿病伤口中 B 族链球菌的发病机制
- 批准号:
10676441 - 财政年份:2023
- 资助金额:
$ 12.9万 - 项目类别:
Moving maternal Group B Streptococcal vaccines into clinical effectiveness trials.
将孕产妇 B 组链球菌疫苗纳入临床有效性试验。
- 批准号:
MR/X011100/1 - 财政年份:2023
- 资助金额:
$ 12.9万 - 项目类别:
Fellowship
The impact of gestational diabetes on Group B Streptococcal virulence and host immune response
妊娠糖尿病对 B 族链球菌毒力和宿主免疫反应的影响
- 批准号:
10738456 - 财政年份:2023
- 资助金额:
$ 12.9万 - 项目类别:
Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate Models
在临床前小鼠和非人灵长类动物模型中确定 A 组链球菌疫苗抗原最有效的佐剂
- 批准号:
10577066 - 财政年份:2023
- 资助金额:
$ 12.9万 - 项目类别:
Novel Therapeutic Approach to Invasive Group A Streptococcal Disease
侵袭性 A 组链球菌疾病的新治疗方法
- 批准号:
10452033 - 财政年份:2022
- 资助金额:
$ 12.9万 - 项目类别:
A Phase 1 Clinical Trial of a Peptide-Based Group A Streptococcal Vaccine
基于肽的 A 组链球菌疫苗的 1 期临床试验
- 批准号:
466323 - 财政年份:2022
- 资助金额:
$ 12.9万 - 项目类别:
Operating Grants
A Phase 1 Clinical Trial of a Peptide-Based Group A Streptococcal Vaccine
基于肽的 A 组链球菌疫苗的 1 期临床试验
- 批准号:
474602 - 财政年份:2022
- 资助金额:
$ 12.9万 - 项目类别:
Operating Grants
Novel Therapeutic Approach to Invasive Group A Streptococcal Disease
侵袭性 A 组链球菌疾病的新治疗方法
- 批准号:
10546470 - 财政年份:2022
- 资助金额:
$ 12.9万 - 项目类别:
Contribution of immune modulation, metabolism, and microbiota to Group B Streptococcal urinary tract infection
免疫调节、代谢和微生物群对 B 族链球菌尿路感染的影响
- 批准号:
10366247 - 财政年份:2021
- 资助金额:
$ 12.9万 - 项目类别:
Calprotectin modulates Group B streptococcal colonization and disease
钙卫蛋白调节 B 族链球菌定植和疾病
- 批准号:
10190492 - 财政年份:2021
- 资助金额:
$ 12.9万 - 项目类别:














{{item.name}}会员




